azacitidine has been researched along with Thrombocythemia, Essential in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alonso-Dominguez, JM; Atance-Pasarisas, M; Blas, C; Castaño-Bonilla, T; Cotti-Ferrari, MJ; Franganillo-Suárez, A; Lainez-González, D; Llamas-Sillero, P; Martínez-Díez, Y; Rodríguez-Pinilla, SM; Salgado-Sánchez, R | 1 |
| Anaclerico, B; Andriani, A; Aroldi, A; Breccia, M; Carmosino, I; Centra, A; Di Veroli, A; Elli, E; Fianchi, L; Foà, R; Latagliata, R; Martini, V; Montanaro, G; Montanaro, M; Niscola, P; Trapè, G; Villivà, N; Voso, MT | 1 |
| Ichikawa, M; Iizuka, H; Kurokawa, M; Masuda, A; Nannya, Y; Yamamoto, G; Yatomi, Y; Yoshimi, A | 1 |
| Bhatt, VR | 1 |
| Bhagat, TD; Bhattacharyya, S; Christopeit, M; Greally, JM; Maciejewski, JP; McDevitt, M; Melnick, AM; Mo, Y; Moliterno, A; Nischal, S; Pardanani, A; Sohal, D; Steidl, U; Suzuki, M; Verma, A; Will, B; Yu, Y; Zhou, L | 1 |
| Cortes, JE; Garcia-Manero, G; Kantarjian, H; Kornblau, S; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Tong, W; Verstovsek, S | 1 |
1 trial(s) available for azacitidine and Thrombocythemia, Essential
| Article | Year |
|---|---|
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; DNA Methylation; Female; Humans; Janus Kinase 2; Male; Middle Aged; Neutropenia; Polycythemia Vera; Primary Myelofibrosis; Thrombocythemia, Essential; Treatment Outcome | 2008 |
5 other study(ies) available for azacitidine and Thrombocythemia, Essential
| Article | Year |
|---|---|
Spontaneous Remission of Acute Myeloid Leukemia: A Case Report.
Topics: Aged; Azacitidine; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Remission, Spontaneous; Thrombocythemia, Essential | 2022 |
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Melphalan; Middle Aged; Mutation; Myeloproliferative Disorders; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Remission Induction; Retrospective Studies; Thrombocythemia, Essential; Treatment Outcome | 2019 |
Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia.
Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Administration Schedule; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thrombocythemia, Essential; Treatment Outcome | 2013 |
Leukemic transformation in essential thrombocythemia.
Topics: Azacitidine; Cell Transformation, Neoplastic; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Mutation; Prognosis; Risk Factors; Stem Cell Transplantation; Thrombocythemia, Essential; Transplantation, Homologous | 2014 |
Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; Decitabine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Female; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Polycythemia Vera; Primary Myelofibrosis; Proto-Oncogene Proteins; Repressor Proteins; Thrombocythemia, Essential | 2013 |